Clinical Trials for Lung Cancer TreatmentsEvery year, there are more than 200,000 new cases of lung cancer in the U.S. The good news is that over the past decade, lung cancer death rates have been dropping thanks to improvements in treatments made possible by clinical trials. At Regional Cancer Care Associates, we conduct more than 300 advanced clinical trials. To see if a lung cancer clinical trial is right for you, contact RCCA at 201-669-4706.
Defining Clinical TrialClinical trials are research studies that test the safety and effectiveness of new medical approaches to prevent, detect, diagnose and cure certain diseases. When it comes to lung cancer, these studies provide data that help give medical professionals insight into new drugs, treatment techniques and devices and their ability to treat cancer patients. Before being offered as a clinical trial, the therapies must undergo a lengthy research process in a laboratory. When they finally become available to the medical community, these treatments will be meticulously designed. Prior to giving consent for a clinical trial, patients will receive in-depth information about the various aspects of the treatment, including all possible risks and benefits.
The Clinical Trial AdvantageLung cancer treatments are constantly being developed, but before they can be approved, they must be tested for human use. As a participant in a clinical trial, you’ll receive access to innovative treatments that have yet to hit the market. Besides presenting you with cutting-edge medical therapies, clinical trials give you the chance to make a difference in the future of lung cancer care. Clinical trials are also considered an affordable option for lung cancer patients. In fact, all cost of care is covered by the sponsoring company. At RCCA specifically, we always put the safety and wellbeing of our clinical trial participants first – an institutional review board and scientific experts will closely monitor trial protocols to ensure strict regulations are enforced throughout the process.
Lung Cancer Clinical Trials at RCCAWant more information about enrolling in a lung cancer clinical trial? Make an appointment at your nearest RCCA location to speak with a cancer care specialist about your clinical trial eligibility.
A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC
A Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA)
A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer
Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor
A Phase II single-arm trial to investigate tepotinib in stage IIIB/IV adenocarcinoma of the lung with MET exon 14 (METex14) skipping alterations after failure of at least one prior active therapy, including a platinum-doublet-containing regimen
A Phase 1b Study of LY2835219 in Combination with Multiple Single-Agent Options for Patients with Stage IV NSCLC
“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “
A Phase Ib Multi-Cohort Trial of MK-3475 in Subjects with Hematologic Malignancies
A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies